Neuronetics Reports Updated Q4 Results; Net Loss $(0.33)

Benzinga
28 Mar

Fourth Quarter 2024 Results for the Three Months Ended December 31, 2024

  • a $0.6 million reduction in the 2024 bonus accrual that the Company assumed in connection with its acquisition of Greenbrook, resulting in an increase in the Company's operating expenses from $25.8 million, as reported in the Initial Release, to $26.4 million under applicable purchasing accounting principles;
  • an increase in the net loss and net loss per share from $(12.2) million and $(0.33), respectively, as reported in the Initial Release, to $(12.7) million and $(0.34), respectively; and
  • a decrease in the adjusted EBITDA from $0.1 million, as reported in the Initial Release, to $(0.4) million.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10